Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

749
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
749
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

516
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
516

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Targeting GLP1R and IL17A suppresses obesity-induced leukemia in an oncogenic PTPN11 mutation-driven model.

The Journal of clinical investigation·2026
Same author

STIP1/HOP promotes the formation of cytotoxic α-synuclein oligomers.

Molecular neurodegeneration advances·2026
Same author

An automated workflow for quantifying the formation of synuclein aggregates in human dopaminergic neurons.

Methods (San Diego, Calif.)·2026
Same author

N-terminal acetylation reduces synuclein pathology in models of Parkinson's disease.

Neurobiology of disease·2026
Same author

Cell type transcriptomic modules reveal shared molecular mechanisms in Alzheimer's and Parkinson's disease.

GigaScience·2026
Same author

A high-content imaging workflow to screen for molecules that reduce cellular uptake of α-synuclein preformed fibrils.

Methods (San Diego, Calif.)·2026
Same journal

Evidence for progressive neurodegeneration in iatrogenic cerebral amyloid angiopathy.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Human brain connectome profiles mediate the relationship between pathology burden and clinical phenotypes in Alzheimer's disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Kat5 cKO mouse replicates biological domain signatures associated with Alzheimer's disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Evaluation of CSF and plasma tau species as fluid surrogate candidates for tau PET in prodromal to moderate Alzheimer's disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Associations of self-reported obstructive sleep apnea with cognition and dementia risk in cognitively unimpaired middle-aged adults.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Inflammation profiles in Alzheimer's disease relate to cognition and neurodegeneration.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
查看所有相关文章

相关实验视频

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

生物标志物 生物标志物

Rodrigo Sandoval1, Vladislav Novikov1, Anoosha Attaran2

  • 1University of Western Ontario, London, ON, Canada.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 26, 2025
PubMed
概括
此摘要是机器生成的。

触摸屏认知测试可以改善临床前药物评估的同核蛋白病变. 与Cinpanemab不同的是,PU-AD显示出广泛的神经保护,在小鼠中拯救认知和运动缺陷.

更多相关视频

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

相关实验视频

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

科学领域:

  • 神经科学是一个神经科学.
  • 药理学 药理学 是一个学科.
  • 药物开发 药物开发

背景情况:

  • 像阿尔茨海默氏症和帕金森症这样的神经退行性疾病涉及错误折叠的蛋白质积累 (粉样β,,α-synuclein).
  • 目前的疗法没有改变疾病,动物模型往往缺乏临床疗效的预测有效性.
  • 认知缺陷,如逆向学习受损,在同核蛋白病变中被发现,突出显示了在临床前测试中需要认知生物标志物的需要.

研究的目的:

  • 评估基于触摸屏的认知测试是否提高了临床前药物测试对同核蛋白病变的预测有效性.
  • 为了评估PU-AD的疗效,一个HSP90突细胞干扰剂,和Cinpanemab,一个抗α-synuclein抗体,在synucleinopathy的小鼠模型中.

主要方法:

  • 给小鼠 (M83) 注射了α-synuclein预制纤维素 (PFFs),以诱导同核蛋白病变.
  • 认知灵活性是通过对对视觉歧视和反转 (PVD-R) 触摸屏任务来评估的.
  • 给出了PU-AD和Cinpanemab,并评估了认知,运动,病理和神经炎症的结果.

主要成果:

  • 患有同核蛋白病变的小鼠比运动障碍更早表现出认知缺陷.
  • PU-AD治疗显著改善了认知和运动功能,表明神经保护作用.
  • 辛巴尼马布治疗没有改善认知或运动症状,与失败的临床试验一致.

结论:

  • 触摸屏认知测试改善了用于同核蛋白病变的临床前药物评估的预测有效性.
  • 通过改善认知和运动障碍,PU-AD显示出广泛的治疗潜力.
  • 该研究强调了在临床前模型中的某些候选药物 (例如,Cinpanemab) 的局限性以及认知评估的价值.